NCT03090893View on ClinicalTrials.gov

Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 1, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Antithrombin Deficiency Type 2
Interventions
DRUG

ATryn continuous infusion

replenish serum thrombin levels

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

rEVO Biologics
All Listed Sponsors
collaborator

rEVO Biologics

INDUSTRY

lead

Mayo Clinic

OTHER

NCT03090893 - Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients | Biotech Hunter | Biotech Hunter